https://www.selleckchem.com/products/vb124.html BACKGROUND/AIM It is well known that patients with chronic heart failure and hypokalaemia have increased mortality risk. We investigated the impact of normalising serum potassium following an episode of hypokalaemia on short-term mortality among patients with chronic heart failure. METHODS AND RESULTS We identified 1673 patients diagnosed with chronic heart failure who had a serum potassium measurement under 3.5 mmol/l within 14 days and one year after initiated medical treatment with both loop diuretics and angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers. A second serum potassium measurement was required 8-30 days after the episode of hypokalaemia. All-cause mortality and cardiovascular mortality was examined within 90 days from the second serum potassium measurement. Mortality was examined according to six predefined potassium groups derived from the second measurement less then 3.5 mmol/l (n = 302), 3.5-3.7 mmol/l (n = 271), 3.8-4.1 mmol/l (n = 464), 4.2-4.4 mmol/l (n = 270), 4.37; 95% confidence interval 0.97-1.95) had a trend toward increased risk of cardiovascular mortality compared to the reference. CONCLUSION Patients with chronic heart failure and hypokalaemia, who after 8-30 days remained hypokalaemic, had a significantly higher 90-day all-cause mortality risk compared to patients in the reference group (3.8-4.1 mmol/l). Patients with chronic heart failure and hypokalaemia, who after 8-30 days had the serum potassium level increased to a level within 5.1-8.0 mmol/l, had both a significantly higher 90-day all-cause mortality risk and cardiovascular mortality risk compared to patients in the reference group (3.8-4.1 mmol/l).BACKGROUND Contemporary, nationally representative 30-day readmissions data after carotid artery stenting (CAS) and carotid endarterectomy (CEA) are lacking. METHODS Patients undergoing CAS or CEA were identified from the 2013 to 2014 Nationwide Readmissions Data